Latest News for: phase 1 clinical trial

Edit

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of E-602 (HLX79), a ...

The Galveston Daily News 08 Aug 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Aug 7, 2025-- ....
Edit

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms (Form 8-K) (Abcellera Biologics Inc)

Public Technologies 08 Aug 2025
) AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms ... AbCellera has initiated a Phase 1 clinical trial of ABCL575, ...
Edit

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Form 8-K) (Kiora Pharmaceuticals Inc)

Public Technologies 08 Aug 2025
) Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases ... •Initiated KLARITY, a Phase 2 clinical trial ...
Edit

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

PR Newswire 06 Aug 2025
... that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, and has administered a fifth weekly dose to the first patient.
Edit

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient (Form 8-K) (Metavia Inc)

Public Technologies 06 Aug 2025
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 ... dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, and has administered a fifth weekly dose to the first patient.
Edit

Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors

PR Newswire 05 Aug 2025
... to announce the completion of the first patient enrollment  in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital.
Edit

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan (NicOx SA)

Public Technologies 05 Aug 2025
) Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan Triggers a €2 million milestone payment to Nicox August 5, 2025 - release at 7.30 am CET.
Edit

Atavistik Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ATV-1601 in Patients ...

Nasdaq Globe Newswire 04 Aug 2025
04, 2025 (GLOBE NEWSWIRE) -- Atavistik Bio, a biotechnology ...
Edit

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

PR Newswire 31 Jul 2025
Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of ...
Edit

Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for ...

Nasdaq Globe Newswire 29 Jul 2025
The Phase 3 clinical trial of sovateltide, ...
Edit

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in ...

Nasdaq Globe Newswire 28 Jul 2025
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – ... .
Edit

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of

Hastings Tribune 28 Jul 2025
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – ... .
Edit

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy (Alterity Therapeutics Ltd)

Public Technologies 28 Jul 2025
) Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy ... The ATH434-202 Phase 2 clinical trial was an open label study in advanced MSA.
Edit

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy (Form 6-K) (Alterity Therapeutics Ltd)

Public Technologies 28 Jul 2025
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy ... The ATH434-202 Phase 2 clinical trial was an open label study in advanced MSA.
Edit

Class I New Drug Pemefolacianine Completes Phase I Clinical Trial, Advancing Intraoperative Precision Diagnosis (Frost & Sullivan)

Public Technologies 28 Jul 2025
(Nuoyuan Medical) has successfully completed a Phase I clinical trial in China for its independently developed Class I new drug, Pemefolacianine, with positive outcomes ... The Results of Pemefolacianine Phase I Clinical Trial in China.

Article Search

tools
×
×
×
×